Key result
Rivaroxaban successfully treats a patient with cancer-associated VTE and HIT without recurrence over 3 months.
Why the study?
Low molecular weight heparin is first-line therapy for acute cancer-associated venous thromboembolism, but heparin-induced thrombocytopenia is a life-threatening adverse reaction that complicates treatment.
Does rivaroxaban prevent recurrent thrombosis and bleeding in a patient with cancer-associated venous thromboembolism and heparin-induced thrombocytopenia?
Case Report (n=1)
Does rivaroxaban prevent recurrent thrombosis and bleeding in a patient with cancer-associated venous thromboembolism and heparin-induced thrombocytopenia?
Rivaroxaban may be a safe and effective alternative anticoagulant for treating cancer-associated venous thromboembolism in patients who develop heparin-induced thrombocytopenia.
Answers are grounded in this paper and cite their sources.
May support rivaroxaban in cancer VTE with HIT; hypothesis-generating and requires prospective validation.
Low molecular weight heparin (LMWH) is the first-line therapy in acute cancer-associated venous thromboembolism (CAT). However, heparin-induced thrombocytopenia (HIT) is a life-threatening adverse drug reaction that occurs in anticoagulation therapy with LMWH. This article reports the case of a 66-year-old Chinese male who received nadroparin 4100IU twice daily for treating CAT. Unfortunately, the epistaxis persisted and the blood count examination revealed serious thrombocytopenia on postoperative day 5. The patient was diagnosed with HIT and thereafter LMWH therapy was replaced with rivaroxaban. During three months follow-up, the patient had a good recovery without recurrent CAT or bleeding.
No takes yet. Share an insight, caveat, or question.
Le et al. (2019) conducted a case report in Cancer-associated venous thromboembolism and heparin-induced thrombocytopenia (n=1). Rivaroxaban was evaluated on recurrent CAT or bleeding. Rivaroxaban successfully treated a patient with cancer-associated venous thromboembolism and heparin-induced thrombocytopenia, resulting in no recurrent thrombosis or bleeding over 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: